PLC (NASDAQ: TCBP), a biotechnology firm with a market capitalization of $33.08 million engaged in developing gamma-delta T cell therapies, announced today significant progress in its ACHIEVE Phase 2B ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies ...

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

Celularity Inc.’s CELU share price has dipped by 11.11%, which has investors questioning if this is right time to buy.

Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 15.00%, which has investors questioning if this is right time ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...

Trenchant partnered with Autolomous, integrating its digital solution into its CGT manufacturing platform, for faster production and lower costs.

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

On June 2, 2024, Caribou issued a press release announcing that it had "presented updated clinical data from the ongoing ...